SBFMHealthcare · Drug Manufacturers - Specialty & Generic

SBFM Stock Forecast: Sunshine Biopharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$1.17

+0.86% on the day

The 1 Wall Street analysts covering Sunshine Biopharma, Inc. hold a median 12-month price target of $56 — +4686.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 22 Aug 2026 — in the upper half.

Market cap

$4.5M

Ticker Nerd rank

62 / 100

Median analyst target

$56

Analysts covering

Total return, dividends reinvested

+1.7%

−33.1%

YTD

−90.5%

−91.8%

From 52W high

−94.7%

From 52W low

+4.5%

$22

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SBFM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sunshine Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Quality

Growth

Accruals

Issuance

Volatility

Momentum

Value

Size (97): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SBFM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SBFM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $56Median $56High $56

The green dot is the last close — the median target sits +4686.3% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
8 Oct 2025	Aegis Capital	Reiterates	Buy	$7.00
5 Dec 2024	Aegis Capital	Reiterates	Buy	—
7 Aug 2023	Aegis Capital	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SBFM appears on the weeks it earns a place.

Estimates

SBFM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Sunshine Biopharma, Inc. (SBFM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.2×
Price / sales: 0.1×
Price / book: 0.0×
EV / EBITDA: 1.8×

Growth & margins

Revenue growth (YoY): −1.6%
Earnings growth (YoY): −9.1%
Gross margin: 27.0%
Operating margin: −17.4%
Net margin: −16.5%

Returns & dividend

Return on equity: −21.9%
Return on assets: −9.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SBFM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
SBFMSunshine Biopharma, Inc.	$4.5M	62
INMInMed Pharmaceuticals, Inc.	$4.8M	23
SXTCChina Sxt Pharmaceuticals, Inc.	$5.4M	9
YCBDcbdMD, Inc.	$5.7M	27
GELSGelteq Ltd.	$6.0M	12
SNOASonoma Pharmaceuticals, Inc.	$6.4M	31
PRFXPRF Technologies Ltd.	$3.0M	3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sunshine Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SBFM news & analysis

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

Accesswire · 19 Aug 2026positive

Sunshine Biopharma announced Canadian regulatory approval for its generic Enalapril tablets in four dosage strengths (2.5mg, 5mg, 10mg, and 20mg), the generic equivalent of Vasotec. The company expects the tablets to begin shipping to Canadian pharmacies by year-end 2026.

Why it matters — This approval expands Sunshine Biopharma's product portfolio into the large global anti-hypertensive drug market.

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Accesswire · 7 Aug 2026positive

Sunshine Biopharma announced the launch of its generic Amoxicillin formulation in Canada and has begun shipping the antibiotic to Canadian pharmacies in multiple dosages and strengths. The company stated the global Amoxicillin market is projected to reach approximately $6.4 billion by 2031.

Why it matters — The launch expands Sunshine Biopharma's portfolio of essential prescription medications and adds a new revenue stream in a growing global antibiotics market.

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

Accesswire · 4 Aug 2026positive

Sunshine Biopharma announced Canadian regulatory approval for its generic Dienogest 2mg tablets, the generic equivalent of the brand Visanne, which is first-line therapy for pelvic pain associated with endometriosis. This entry targets the $2.8 billion global dienogest market.

Why it matters — SBFM watchers would care because the approval expands the company's portfolio into the growing endometriosis treatment market, projected to reach $5.2 billion by 2034.

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval

Benzinga · 4 Aug 2026positive

Sunshine Biopharma Inc. (NASDAQ:SBFM) announced that it received regulatory approval to introduce its 2mg generic Dienogest tablets to the Canadian market. The approval covers a women's health drug.

Why it matters — SBFM watchers would care because the approval opens up a new market in Canada for the company's women's health product.

Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

Accesswire · 28 July 2026positive

Health Canada has approved Sunshine Biopharma's generic Ondansetron tablets in 4mg and 8mg strengths for the Canadian market. Ondansetron is the generic equivalent of the brand-name drug Zofran, used to treat chemotherapy-induced nausea and vomiting.

Why it matters — This approval expands Sunshine Biopharma's product offerings into the Canadian market with a generic alternative to a widely used chemotherapy-support medication.

FAQ

Frequently asked questions about SBFM stock

What is the SBFM stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Sunshine Biopharma, Inc. have a median 12-month price target of $56, with estimates ranging from $56 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SBFM stock a buy right now?

Of the 1 analysts covering Sunshine Biopharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sunshine Biopharma, Inc. 62 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SBFM?

As at 22 Aug 2026, Sunshine Biopharma, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will SBFM stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +4686.3% from the last close, and Ticker Nerd's factor model ranks Sunshine Biopharma, Inc. 62 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SBFM stock forecast for 2030?

No analyst covering Sunshine Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SBFM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $56 over the next 12 months.

How has SBFM stock performed over the past year?

Sunshine Biopharma, Inc. returned -91.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sunshine Biopharma, Inc. do?

Sunshine Biopharma Inc. is a pharmaceutical company focused on the research, development, commercialization, and distribution of medicines across oncology, antivirals, and other therapeutic areas.

What is the latest news on SBFM?

The most recent item we track (Accesswire, 19 Aug 2026): "Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market". Sunshine Biopharma announced Canadian regulatory approval for its generic Enalapril tablets in four dosage strengths (2.5mg, 5mg, 10mg, and 20mg), the generic equivalent of Vasotec. The company expects the tablets to begin shipping to Canadian pharmacies by year-end 2026.

Company

About Sunshine Biopharma, Inc.

Sunshine Biopharma Inc. is a pharmaceutical company focused on the research, development, commercialization, and distribution of medicines across oncology, antivirals, and other therapeutic areas. Through its commercial operations, the company markets generic prescription drugs in Canada, including treatments used for cholesterol management, bacterial infections, and nausea relief, primarily through its Nora Pharma subsidiary. Sunshine Biopharma also works on biosimilar products and preclinical drug candidates aimed at cancer and viral diseases, supporting a portfolio that spans approved medicines and experimental programs. In addition to prescription pharmaceuticals, the company is involved in science-based nutritional supplements, giving it a broader presence in the healthcare market. Sunshine Biopharma Inc. plays a role in supplying affordable therapeutic options and advancing drug development in regulated pharmaceutical markets.

CEO Dr. Steve N. Slilaty Ph.D. · 50 employees · United States · https://sunshinebiopharma.com